查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1866947

非那雄胺市场依给药途径、产品类型、规格、适应症、通路和最终用户划分－2025-2032年全球预测

Finasteride Market by Route Of Administration, Product Type, Strength, Indication, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，非那雄胺市场规模将成长至 1.5472 亿美元，复合年增长率为 2.92%。

主要市场统计数据
基准年 2024 1.2288亿美元
预计年份：2025年 1.2655亿美元
预测年份：2032年 1.5472亿美元
复合年增长率 (%) 2.92%

引言部分清楚地概述了非那雄胺在泌尿系统和皮肤科的临床应用、製剂选择和市场趋势。

非那雄胺仍是泌尿系统和皮肤科领域重要的小分子治疗药物，对良性前列腺增生和男性型脱髮症有持续的临床效用。该分子的安全性和有效性已透过数十年的临床应用得到充分证实，而近期的临床讨论已转向差异化製剂、患者依从性和风险沟通。随着市场参与企业重新审视其产品组合和分销策略，清晰了解製剂选择、监管预期和终端用户趋势对于持续的商业性成功至关重要。

监管变革、製剂创新、远距远端医疗应用和供应链韧性如何重塑非那雄胺市场的竞争格局

非那雄胺市场正经历着一场变革性的转变，其驱动力包括监管政策的调整、製剂的创新以及临床实践模式的改变。品牌药专利到期加剧了学名药的激烈竞争，导致商业性重心转向差异化製剂，例如外用溶液和泡沫剂，以及旨在提高耐受性和依从性的新型给药系统。同时，临床医师和病患对个人化给药策略（包括低剂量方案）的兴趣日益浓厚，这推动了以1毫克和5毫克製剂为重点的产品研发。

评估2025年美国累积关税对原料药采购及成品药製剂经济效益的商业性影响

2025年美国累积关税的实施，对依赖跨境供应链的非那雄胺生产商、经销商和原料供应商而言，已成为关键的营运转捩点。这些关税针对活性药物成分（API）进口和成品製剂，提高了到岸成本，迫使相关人员重新评估筹资策略。为此，许多企业正在加快与契约製造和API生产商的对话，寻求地理多元化，并寻找能够降低关税风险、同时又能保证产品品质和合规性的替代供应商。

详细的細項分析揭示了给药途径、产品分类、剂量、临床适应症、分销管道和最终用户环境如何驱动策略选择。

了解按给药途径、产品类型、规格、适应症、分销管道和最终用户分類的市场细分，对于识别商业性机会和临床价值的交汇点至关重要。给药途径分为口服和外用製剂，口服製剂再细分为胶囊和锭剂，外用製剂又细分为泡沫剂和溶液剂。这些差异对依从性、耐受性和市场定位具有实际意义。口服片剂和胶囊剂更受习惯于全身治疗的配药医生的青睐，而外用泡沫剂和溶液剂则通常用于解决全身暴露问题和局部耐受性方面的考虑。

美洲、欧洲、中东和非洲以及亚太地区的区域特征将决定监管方式、製造地和商业策略。

区域趋势影响需求驱动因素、法规结构与供应链考量。深入了解美洲、欧洲、中东和非洲以及亚太地区对于战略规划至关重要。在美洲，成熟的监管管道、完善的配製流程和广泛的保险覆盖范围，使得口服和外用製剂的市场接受度都较为稳定。然而，支付方的严格审查和以价值为导向的合约条款正日益影响产品定位和报销谈判。此外，美洲拥有完善的临床研究网络，有利于核准后监测和真实世界数据的产生。

竞争情报和商业情报揭示了创新者、非专利生产商和战略联盟如何推动差异化和商业化运作。

主要企业之间的竞争行为反映了在保护现有业务价值和透过製剂研发、生命週期管理和分销管道创新实现差异化之间的平衡。品牌公司专注于透过製剂授权和针对特定适应症的宣传来维护品牌价值，而非专利生产商则利用其规模、成本效益和分销网络来扩大市场覆盖面。跨国公司往往强调监管一致性和跨境供应的可靠性，而本土公司则通常在灵活性、本地市场知识和定价应对力方面竞争。

为製造商和相关人员提供切实可行的、优先排序的建议，以增强产品差异化、供应多元化、通路策略以及与支付方的合作。

为了获得可持续的竞争优势，产业领导者应采取一系列协同措施，整合临床差异化、供应链韧性和通路优化。首先，应投资于製剂多样化，推广局部用药替代方案和便捷的给药系统，以解决耐受性和依从性问题，同时以临床证据支持局部暴露和安全性声明。其次，应优先考虑原料药(API) 和成品製剂的供应链多样化，透过对多家地理位置分散的供应商进行资格认证，并考虑近岸生产方案，以降低关税风险和物流中断的影响。

我们采用透明、严谨的混合方法研究方法，将第二手资料综合和对关键相关利益者的访谈与稳健的检验和品管相结合。

本分析的调查方法整合了多方面的证据，以确保研究结果的稳健性和可重复性，同时最大限度地减少偏差。全面的二级研究阶段整合了同行评审文献、监管指导文件、临床试验註册资讯以及公开的行业和政策出版物，为临床适应症、製剂科学和行业趋势建立背景。一级研究则透过对临床医生、医院药剂师、采购专家、供应链专业人员和商业领袖进行结构化访谈，补充了上述资讯来源，以收集一线观点并检验战略意义。

权威的综合分析强调，製剂设计、供应链韧性和跨职能执行是支撑非那雄胺策略成功的三大支柱。

总之，要驾驭非那雄胺市场，需要对製剂选择、市场细分动态、区域差异以及新兴政策阻力有深入的了解。专利产品的历史地位与学名药竞争之间的相互作用，促使商业性重心转向透过外用製剂、低剂量策略和更强有力的患者支持来实现差异化。同时，贸易政策的发展和关税措施凸显了供应链多元化以及与海关和贸易相关人员积极互动的重要性。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 推出新型外用非那雄胺製剂，可最大限度减少全身暴露和副作用。
  • 拓展远端医疗平台：提供线上非那雄胺咨询和配药服务
  • 新兴市场契约製造对非专利仿製药生产的投资激增
  • 越来越多的临床试验正在评估低剂量非那雄胺治疗女性型脱髮症的治疗方法
  • 数位化依从性监测解决方案的兴起，用于追踪患者对非那雄胺治疗方案的依从性
  • 非那雄胺与局部生长因子合併使用以促进头髮生长的联合治疗的出现
  • 品牌非那雄胺专利到期对定价策略和成本绩效的学名药上市的影响
  • 消费者对替代雄性激素抑制剂和天然来源的非那雄胺类似物在预防脱髮方面的兴趣日益浓厚。

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 非那雄胺市场依给药途径划分

  • 口服
    • 胶囊
    • 药片
  • 外用药物
    • 形式
    • 解决方案

9. 非那雄胺市场依产品类型划分

  • 品牌产品
    • 领先品牌
    • 授权品牌
  • 学名药
    • 国内製造商
    • 跨国製造商

第十章 非那雄胺市场（依强度划分）

  • 1mg
  • 5mg

第十一章 非那雄胺市场依适应症划分

  • 脱髮症
    • 女性型脱髮症
    • 雄性脱髮症
  • 良性摄护腺增生
    • 轻度良性前列腺增生
    • 中度至重度良性摄护腺增生

第十二章 非那雄胺市场依通路划分

  • 医院药房
    • 私立医院
    • 公立医院
  • 网路药房
    • 製造商官方网站
    • 第三方电子零售商
  • 零售药房
    • 连锁药局
    • 独立药房

第十三章 非那雄胺市场（以最终用户划分）

  • 诊所
    • 皮肤科诊所
    • 泌尿系统诊所
  • 居家医疗
    • 自我治疗
  • 医院
    • 私立医院
    • 公立医院

第十四章 非那雄胺市场区域划分

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 非那雄胺市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国非那雄胺市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Merck & Co., Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
    • Sandoz International GmbH
    • Dr. Reddy's Laboratories Limited
    • Lupin Limited
    • Sun Pharmaceutical Industries Limited
    • Cipla Limited
    • Aurobindo Pharma Limited
    • Alembic Pharmaceuticals Limited
Product Code: MRR-CD5A9334D4CB

The Finasteride Market is projected to grow by USD 154.72 million at a CAGR of 2.92% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 122.88 million
Estimated Year [2025] USD 126.55 million
Forecast Year [2032] USD 154.72 million
CAGR (%) 2.92%

An incisive introduction that frames clinical relevance, formulation choices, and market forces shaping finasteride strategy across urology and dermatology

Finasteride remains a pivotal small-molecule therapeutic across urology and dermatology, with enduring clinical utility for benign prostatic hyperplasia and androgenic alopecia. The molecule's safety and efficacy profile has been well-characterized through decades of clinical use, and recent clinical conversations have shifted toward differentiated formulations, patient adherence, and risk communication. As market participants recalibrate portfolios and distribution strategies, a clear understanding of formulation choices, regulatory expectations, and end-user dynamics is essential for sustained commercial success.

In parallel, healthcare systems are adapting to changing patterns of outpatient care, telemedicine-driven prescribing, and a more informed patient base seeking topical alternatives and lower-dose regimens. These trends are altering prescribing behavior and creating new opportunities for manufacturers able to demonstrate superior tolerability, convenience, or cost-effectiveness. Moreover, the interplay between branded innovators and generic manufacturers continues to shape clinical access and pricing dynamics, urging strategic clarity on product differentiation and lifecycle management.

This introduction frames the subsequent analysis by highlighting why formulation strategy, distribution channel optimization, and responsive regulatory engagement are core to navigating a market environment characterized by heightened competition and evolving patient expectations. The following sections unpack transformative forces, tariff impacts, segmentation nuances, regional variances, competitive behavior, tactical recommendations, methodological rigor, and concluding implications for leaders evaluating finasteride-related opportunities.

How regulatory evolution, formulation innovation, telemedicine adoption, and supply chain resilience are reshaping competitive positioning within the finasteride landscape

The finasteride landscape is undergoing transformative shifts driven by regulatory adaptation, formulation innovation, and changing clinical practice patterns. Patent expirations for originator products have facilitated robust generics competition, which in turn has shifted commercial emphasis toward formulation differentiation such as topical solutions and foams and novel delivery systems that address tolerability and adherence. Concurrently, clinicians and patients are increasingly attentive to individualized dosing strategies, including lower-strength regimens, which have catalyzed product development efforts focused on 1 mg and 5 mg presentations.

Meanwhile, digital health and telemedicine platforms are reshaping prescribing workflows, enabling remote consultations and direct-to-patient distribution that accelerate treatment initiation and follow-up. This evolution is complemented by more sophisticated pharmacovigilance and risk communication practices, prompting manufacturers to invest in patient education and post-marketing evidence generation. Additionally, supply chain resilience has become a strategic imperative after recent global disruptions, prompting companies to evaluate near-shore manufacturing, API sourcing diversification, and inventory management strategies.

Together, these shifts are rebalancing competitive dynamics: manufacturers that align clinical differentiation with channel strategies, regulatory foresight, and supply chain robustness stand to secure durable positioning. Conversely, firms that rely solely on price competition may face margin pressure and constrained growth opportunities as stakeholders prioritize value demonstrated through tolerability, convenience, and evidence of long-term outcomes.

Assessing the operational and commercial consequences of cumulative United States tariff measures introduced in 2025 that affect API sourcing and finished-dosage economics

The introduction of cumulative United States tariffs in 2025 has introduced a material operational inflection point for finasteride manufacturers, distributors, and ingredient suppliers that rely on cross-border supply chains. Tariff measures targeting active pharmaceutical ingredient imports and finished-dose products have raised landed costs and compelled stakeholders to reassess sourcing strategies. In response, many organizations are accelerating dialogues with contract manufacturers and API producers to explore geographic diversification and secure alternative suppliers that mitigate tariff exposure while maintaining quality and regulatory compliance.

In addition, the tariff environment has prompted a renewed emphasis on cost-to-serve analysis across distribution channels. Channel economics for hospital pharmacies, retail outlets, and online pharmacies are being re-evaluated to understand how added import duties affect pricing, reimbursement negotiations, and patient affordability. Manufacturers are increasingly modeling the downstream effects of tariffs on formulary positioning and payer conversations, and some are pursuing supply chain reconfiguration to minimize tariff incidence on finished products.

Finally, the tariffs have highlighted the importance of proactive regulatory and trade engagement. Firms that collaborate with trade advisors, customs authorities, and industry consortia are better positioned to identify exemptions, preferential trade pathways, and tariff mitigation approaches. As a result, strategic planning now increasingly integrates trade policy considerations, ensuring that product launches, inventory allocation, and contract negotiations account for tariff-driven cost volatility and the need for operational flexibility.

In-depth segmentation analysis revealing how formulation, product class, dosing, clinical indication, distribution pathways, and end-user settings drive strategic choices

Understanding how the market is segmented across route of administration, product type, strength, indication, distribution channel, and end user is central to identifying where commercial opportunity and clinical value intersect. The route of administration divides into oral and topical formulations, with oral presentations further categorized into capsule and tablet, and topical options further described as foam and solution. These distinctions have practical implications for adherence, tolerability, and positioning: oral tablets and capsules appeal to prescribers familiar with systemic therapy, while topical foams and solutions are often positioned to address concerns about systemic exposure and localized tolerability.

Product type segmentation differentiates branded from generic offerings, with branded products subdivided into innovator brands and licensed brands, and generic products distinguished between local manufacturers and multinational manufacturers. Each category carries implications for regulatory engagement, marketing spend, and payer negotiations. Strength segmentation centers on two clinically relevant doses, 1 mg and 5 mg, and these strengths inform therapeutic intent-lower-dose regimens often align with hair loss indications and higher strengths guide prostate-related therapy.

Indication segmentation separates androgenic alopecia from benign prostatic hyperplasia, with androgenic alopecia further delineated into female pattern hair loss and male pattern baldness, and benign prostatic hyperplasia split into mild BPH and moderate to severe BPH. Distribution channel analysis examines hospital pharmacy, online pharmacy, and retail pharmacy pathways; hospital pharmacies are segmented into private and public institutions, online pharmacies into manufacturer websites and third-party e-retailers, and retail pharmacies into chain and independent formats. End-user segmentation captures clinics, home care, and hospitals with clinics further distinguished between dermatology and urology clinics, home care emphasizing self-medication, and hospitals divided into private and public facilities. These layered segments guide product design, messaging strategy, pricing approach, and channel investments, thereby enabling precise targeting of clinician audiences, patient cohorts, and procurement stakeholders.

Regional dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine regulatory approaches, manufacturing footprints, and commercial strategies

Regional dynamics shape demand drivers, regulatory frameworks, and supply chain considerations, and a granular understanding of the Americas, Europe Middle East & Africa, and Asia-Pacific regions is essential for strategic planning. In the Americas, mature regulatory pathways, established prescribing norms, and widespread insurance coverage create predictable adoption patterns for both oral and topical formulations; however, payer scrutiny and value-based contracting increasingly inform product positioning and reimbursement discussions. The Americas also feature advanced clinical research networks that facilitate post-authorization studies and real-world evidence generation.

In Europe Middle East & Africa, heterogeneity in regulatory requirements and healthcare financing creates a multifaceted landscape. European markets tend to have stringent pharmacovigilance expectations and centralized pricing negotiations, whereas Middle Eastern and African markets may prioritize access and cost-containment. Regional procurement mechanisms and variable patient awareness levels influence uptake of branded versus generic options, and manufacturers often adapt registration and commercial strategies to address local regulatory timelines and channel structures.

Asia-Pacific exhibits a dynamic mix of rapid manufacturing capacity expansion, active generic competition, and growing private-sector delivery. Several countries in the region are significant producers of active pharmaceutical ingredients and finished-dose medicines, which impacts global supply chains and the cost base. At the same time, rising patient awareness, expanding digital health adoption, and evolving regulatory harmonization efforts shape how products are launched and scaled. Together, these regional nuances govern go-to-market sequencing, partnership selection, and investment prioritization across product development, manufacturing footprint, and commercial operations.

Competitive and operational intelligence showing how innovators, generic manufacturers, and strategic partnerships drive differentiation and commercialization execution

Competitive behavior among key companies reflects a balance between protecting legacy franchise value and pursuing differentiation through formulation, lifecycle management, and channel innovation. Innovator companies have focused on maintaining brand relevance through licensed formulations and indication-specific communications, while generics manufacturers leverage scale, cost efficiencies, and distribution networks to capture broad access. Multinational manufacturers tend to emphasize regulatory consistency and cross-border supply reliability, whereas local manufacturers often compete on agility, local market knowledge, and price responsiveness.

Strategic initiatives commonly include licensing agreements, co-promotion partnerships, and selective acquisitions aimed at augmenting formulation portfolios or securing distribution reach in key regions. Clinical evidence generation and patient support programs are increasingly central to maintaining prescriber trust and facilitating long-term adherence, particularly where safety perceptions or tolerability concerns influence prescribing choices. Companies investing in topical platforms, lower-dose presentations, or combination approaches are positioning to address unmet tolerability or convenience gaps that can complement existing oral offerings.

Operationally, leaders are prioritizing supply chain security, regulatory agility, and digital engagement to support remote prescribing and direct-to-patient fulfillment. Those that integrate cross-functional capabilities-commercial, regulatory, medical, and manufacturing-are better equipped to execute rapid product modifications, respond to tariff-driven cost pressures, and negotiate effectively with payers and procurement entities. Overall, competitive dynamics reward companies that align scientific differentiation with pragmatic commercialization and operational resilience.

Practical and prioritized recommendations for manufacturers and stakeholders to strengthen formulation differentiation, supply diversity, channel strategy, and payer engagement

Industry leaders should pursue a coordinated set of actions that align clinical differentiation, supply chain resilience, and channel optimization to capture sustainable advantage. First, invest in formulation diversification by advancing topical alternatives and user-friendly delivery systems that address tolerability and adherence concerns, while ensuring clinical evidence supports claims of localized exposure and safety. Second, prioritize API and finished-dose supply chain diversification by qualifying multiple suppliers across geographies and considering near-shore manufacturing options to mitigate tariff exposure and logistical disruption.

Third, refine channel strategies to reflect evolving patient and prescriber behaviors; this includes strengthening direct-to-patient capabilities through manufacturer websites, partnering with reputable third-party e-retailers for broader reach, and supporting hospital and clinic procurement teams with targeted clinical and economic evidence. Fourth, enhance lifecycle management by strategically aligning branded and licensed offerings with generics strategies, using real-world evidence and post-marketing surveillance to sustain clinician confidence and payer negotiations. Fifth, engage early and constructively with payers, procurement bodies, and regulatory agencies to shape reimbursement pathways and to explore tariff mitigation measures or preferential trade arrangements.

Finally, invest in digital engagement and patient support programs that bolster adherence and long-term outcomes, while using data analytics to understand channel economics and to optimize inventory allocation. By implementing these coordinated steps, leaders can reduce risk, unlock differentiating value propositions, and position portfolios for resilient performance in an increasingly complex environment.

A transparent and rigorous mixed-methods research approach combining secondary synthesis and primary stakeholder interviews with robust triangulation and quality control

The research methodology underpinning this analysis integrates multiple evidence streams to ensure robust, reproducible insights and to minimize bias. A comprehensive secondary research phase synthesized peer-reviewed literature, regulatory guidance documents, clinical trial registries, and open-source trade and policy publications to establish context on clinical indications, formulation science, and trade dynamics. Primary research complemented these sources through structured interviews with clinicians, hospital pharmacists, procurement specialists, supply chain experts, and commercial leaders to capture on-the-ground perspectives and validate strategic implications.

Data triangulation was applied across qualitative inputs and documented sources to reconcile divergent viewpoints and to strengthen confidence in thematic findings. The segmentation framework was developed iteratively, mapping route of administration, product type, strength, indication, distribution channel, and end user to real-world prescribing and procurement behaviors. Quality control procedures included cross-validation of interview transcripts, source auditing, and peer review by subject matter experts to ensure factual accuracy and methodological transparency.

Ethical and compliance standards guided research conduct, protecting respondent confidentiality and ensuring that conclusions were evidence-based. The resulting methodological approach prioritizes replicability and traceability so that stakeholders can understand how insights were derived and apply them to strategic planning, commercialization roadmaps, and operational decision-making.

A conclusive synthesis emphasizing formulation, supply chain resilience, and cross-functional execution as the pillars of successful finasteride strategies

In conclusion, navigating the finasteride landscape requires a nuanced appreciation of formulation choices, segmentation dynamics, regional variations, and emerging policy headwinds. The interplay of patented product legacies and generics competition has shifted commercial emphasis toward differentiation through topical formulations, lower-dose strategies, and stronger patient support. Simultaneously, trade policy developments and tariff measures have underscored the strategic importance of supply chain diversification and proactive engagement with customs and trade stakeholders.

For decision-makers, the priority is to translate these insights into cohesive strategies that align clinical differentiation with channel tactics and operational resilience. This means investing in evidence generation to support new formulations, securing multi-source supply options to mitigate tariff and logistical risk, and adapting commercialization models to a landscape increasingly shaped by telemedicine and direct-to-patient channels. Continued collaboration across functions-medical affairs, regulatory, supply chain, and commercial-will be essential to execute these strategies effectively.

Ultimately, success in this environment will favor organizations that combine scientific rigor, regulatory foresight, and commercial agility to meet clinician expectations and patient needs while managing cost and access dynamics. The following call to action outlines how to obtain the detailed report and arrange a strategic briefing to operationalize these findings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of new topical finasteride formulations to minimize systemic exposure and side effects
  • 5.2. Expansion of telehealth platforms providing virtual finasteride consultations and prescription services
  • 5.3. Surge in investment in generic finasteride production by contract manufacturers in emerging markets
  • 5.4. Increasing clinical trials evaluating low-dose finasteride treatment regimens for female pattern hair loss
  • 5.5. Rise of digital adherence monitoring solutions to track patient compliance with finasteride therapy schedules
  • 5.6. Emergence of combination therapies pairing finasteride with topical growth factors for enhanced hair regrowth outcomes
  • 5.7. Impact of branded finasteride patent expirations on pricing strategies and entry of value oriented generics
  • 5.8. Growing consumer interest in alternative androgen inhibitors and natural finasteride analogs for hair loss prevention

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Finasteride Market, by Route Of Administration

  • 8.1. Oral
    • 8.1.1. Capsule
    • 8.1.2. Tablet
  • 8.2. Topical
    • 8.2.1. Foam
    • 8.2.2. Solution

9. Finasteride Market, by Product Type

  • 9.1. Branded
    • 9.1.1. Innovator Brands
    • 9.1.2. Licensed Brands
  • 9.2. Generic
    • 9.2.1. Local Manufacturer
    • 9.2.2. Multinational Manufacturer

10. Finasteride Market, by Strength

  • 10.1. 1 Mg
  • 10.2. 5 Mg

11. Finasteride Market, by Indication

  • 11.1. Androgenic Alopecia
    • 11.1.1. Female Pattern Hair Loss
    • 11.1.2. Male Pattern Baldness
  • 11.2. Benign Prostatic Hyperplasia
    • 11.2.1. Mild BPH
    • 11.2.2. Moderate To Severe BPH

12. Finasteride Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
    • 12.1.1. Private Hospital
    • 12.1.2. Public Hospital
  • 12.2. Online Pharmacy
    • 12.2.1. Manufacturer Website
    • 12.2.2. Third Party E-Retailer
  • 12.3. Retail Pharmacy
    • 12.3.1. Chain Pharmacy
    • 12.3.2. Independent Pharmacy

13. Finasteride Market, by End User

  • 13.1. Clinics
    • 13.1.1. Dermatology Clinics
    • 13.1.2. Urology Clinics
  • 13.2. Home Care
    • 13.2.1. Self Medication
  • 13.3. Hospitals
    • 13.3.1. Private Hospitals
    • 13.3.2. Public Hospitals

14. Finasteride Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Finasteride Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Finasteride Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Merck & Co., Inc.
    • 17.3.2. Teva Pharmaceutical Industries Ltd.
    • 17.3.3. Viatris Inc.
    • 17.3.4. Sandoz International GmbH
    • 17.3.5. Dr. Reddy's Laboratories Limited
    • 17.3.6. Lupin Limited
    • 17.3.7. Sun Pharmaceutical Industries Limited
    • 17.3.8. Cipla Limited
    • 17.3.9. Aurobindo Pharma Limited
    • 17.3.10. Alembic Pharmaceuticals Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL FINASTERIDE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL FINASTERIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL FINASTERIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL FINASTERIDE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL FINASTERIDE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL FINASTERIDE MARKET SIZE, BY STRENGTH, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL FINASTERIDE MARKET SIZE, BY STRENGTH, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL FINASTERIDE MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL FINASTERIDE MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL FINASTERIDE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL FINASTERIDE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL FINASTERIDE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS FINASTERIDE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA FINASTERIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA FINASTERIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA FINASTERIDE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE FINASTERIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST FINASTERIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA FINASTERIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC FINASTERIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL FINASTERIDE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN FINASTERIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC FINASTERIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION FINASTERIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS FINASTERIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 FINASTERIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO FINASTERIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL FINASTERIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. FINASTERIDE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. FINASTERIDE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. FINASTERIDE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL FINASTERIDE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL FINASTERIDE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL FINASTERIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL FINASTERIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL FINASTERIDE MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL FINASTERIDE MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL FINASTERIDE MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL FINASTERIDE MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL FINASTERIDE MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL FINASTERIDE MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL FINASTERIDE MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL FINASTERIDE MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL FINASTERIDE MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL FINASTERIDE MARKET SIZE, BY CAPSULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL FINASTERIDE MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL FINASTERIDE MARKET SIZE, BY CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL FINASTERIDE MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL FINASTERIDE MARKET SIZE, BY CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL FINASTERIDE MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL FINASTERIDE MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL FINASTERIDE MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL FINASTERIDE MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL FINASTERIDE MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL FINASTERIDE MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL FINASTERIDE MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL FINASTERIDE MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL FINASTERIDE MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL FINASTERIDE MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL FINASTERIDE MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL FINASTERIDE MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL FINASTERIDE MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL FINASTERIDE MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL FINASTERIDE MARKET SIZE, BY FOAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL FINASTERIDE MARKET SIZE, BY FOAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL FINASTERIDE MARKET SIZE, BY FOAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL FINASTERIDE MARKET SIZE, BY FOAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL FINASTERIDE MARKET SIZE, BY FOAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL FINASTERIDE MARKET SIZE, BY FOAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL FINASTERIDE MARKET SIZE, BY SOLUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL FINASTERIDE MARKET SIZE, BY SOLUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL FINASTERIDE MARKET SIZE, BY SOLUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL FINASTERIDE MARKET SIZE, BY SOLUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL FINASTERIDE MARKET SIZE, BY SOLUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL FINASTERIDE MARKET SIZE, BY SOLUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL FINASTERIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL FINASTERIDE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL FINASTERIDE MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL FINASTERIDE MARKET SIZE, BY BRANDED, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL FINASTERIDE MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL FINASTERIDE MARKET SIZE, BY BRANDED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL FINASTERIDE MARKET SIZE, BY BRANDED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL FINASTERIDE MARKET SIZE, BY BRANDED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL FINASTERIDE MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL FINASTERIDE MARKET SIZE, BY BRANDED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL FINASTERIDE MARKET SIZE, BY INNOVATOR BRANDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL FINASTERIDE MARKET SIZE, BY INNOVATOR BRANDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL FINASTERIDE MARKET SIZE, BY INNOVATOR BRANDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL FINASTERIDE MARKET SIZE, BY INNOVATOR BRANDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL FINASTERIDE MARKET SIZE, BY INNOVATOR BRANDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL FINASTERIDE MARKET SIZE, BY INNOVATOR BRANDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL FINASTERIDE MARKET SIZE, BY LICENSED BRANDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL FINASTERIDE MARKET SIZE, BY LICENSED BRANDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL FINASTERIDE MARKET SIZE, BY LICENSED BRANDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL FINASTERIDE MARKET SIZE, BY LICENSED BRANDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL FINASTERIDE MARKET SIZE, BY LICENSED BRANDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL FINASTERIDE MARKET SIZE, BY LICENSED BRANDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL FINASTERIDE MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL FINASTERIDE MARKET SIZE, BY GENERIC, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL FINASTERIDE MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL FINASTERIDE MARKET SIZE, BY GENERIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL FINASTERIDE MARKET SIZE, BY GENERIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL FINASTERIDE MARKET SIZE, BY GENERIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL FINASTERIDE MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL FINASTERIDE MARKET SIZE, BY GENERIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL FINASTERIDE MARKET SIZE, BY LOCAL MANUFACTURER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL FINASTERIDE MARKET SIZE, BY LOCAL MANUFACTURER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL FINASTERIDE MARKET SIZE, BY LOCAL MANUFACTURER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL FINASTERIDE MARKET SIZE, BY LOCAL MANUFACTURER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL FINASTERIDE MARKET SIZE, BY LOCAL MANUFACTURER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL FINASTERIDE MARKET SIZE, BY LOCAL MANUFACTURER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL FINASTERIDE MARKET SIZE, BY MULTINATIONAL MANUFACTURER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL FINASTERIDE MARKET SIZE, BY MULTINATIONAL MANUFACTURER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL FINASTERIDE MARKET SIZE, BY MULTINATIONAL MANUFACTURER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL FINASTERIDE MARKET SIZE, BY MULTINATIONAL MANUFACTURER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL FINASTERIDE MARKET SIZE, BY MULTINATIONAL MANUFACTURER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL FINASTERIDE MARKET SIZE, BY MULTINATIONAL MANUFACTURER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL FINASTERIDE MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL FINASTERIDE MARKET SIZE, BY STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL FINASTERIDE MARKET SIZE, BY 1 MG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL FINASTERIDE MARKET SIZE, BY 1 MG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL FINASTERIDE MARKET SIZE, BY 1 MG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL FINASTERIDE MARKET SIZE, BY 1 MG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL FINASTERIDE MARKET SIZE, BY 1 MG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL FINASTERIDE MARKET SIZE, BY 1 MG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL FINASTERIDE MARKET SIZE, BY 5 MG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL FINASTERIDE MARKET SIZE, BY 5 MG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL FINASTERIDE MARKET SIZE, BY 5 MG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL FINASTERIDE MARKET SIZE, BY 5 MG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL FINASTERIDE MARKET SIZE, BY 5 MG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL FINASTERIDE MARKET SIZE, BY 5 MG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL FINASTERIDE MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL FINASTERIDE MARKET SIZE, BY ANDROGENIC ALOPECIA, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL FINASTERIDE MARKET SIZE, BY ANDROGENIC ALOPECIA, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL FINASTERIDE MARKET SIZE, BY ANDROGENIC ALOPECIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL FINASTERIDE MARKET SIZE, BY ANDROGENIC ALOPECIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL FINASTERIDE MARKET SIZE, BY ANDROGENIC ALOPECIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL FINASTERIDE MARKET SIZE, BY ANDROGENIC ALOPECIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL FINASTERIDE MARKET SIZE, BY ANDROGENIC ALOPECIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL FINASTERIDE MARKET SIZE, BY ANDROGENIC ALOPECIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL FINASTERIDE MARKET SIZE, BY FEMALE PATTERN HAIR LOSS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL FINASTERIDE MARKET SIZE, BY FEMALE PATTERN HAIR LOSS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL FINASTERIDE MARKET SIZE, BY FEMALE PATTERN HAIR LOSS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL FINASTERIDE MARKET SIZE, BY FEMALE PATTERN HAIR LOSS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL FINASTERIDE MARKET SIZE, BY FEMALE PATTERN HAIR LOSS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL FINASTERIDE MARKET SIZE, BY FEMALE PATTERN HAIR LOSS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL FINASTERIDE MARKET SIZE, BY MALE PATTERN BALDNESS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL FINASTERIDE MARKET SIZE, BY MALE PATTERN BALDNESS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL FINASTERIDE MARKET SIZE, BY MALE PATTERN BALDNESS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL FINASTERIDE MARKET SIZE, BY MALE PATTERN BALDNESS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL FINASTERIDE MARKET SIZE, BY MALE PATTERN BALDNESS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL FINASTERIDE MARKET SIZE, BY MALE PATTERN BALDNESS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL FINASTERIDE MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL FINASTERIDE MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL FINASTERIDE MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL FINASTERIDE MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL FINASTERIDE MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL FINASTERIDE MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL FINASTERIDE MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL FINASTERIDE MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL FINASTERIDE MARKET SIZE, BY MILD BPH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL FINASTERIDE MARKET SIZE, BY MILD BPH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL FINASTERIDE MARKET SIZE, BY MILD BPH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL FINASTERIDE MARKET SIZE, BY MILD BPH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL FINASTERIDE MARKET SIZE, BY MILD BPH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL FINASTERIDE MARKET SIZE, BY MILD BPH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL FINASTERIDE MARKET SIZE, BY MODERATE TO SEVERE BPH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL FINASTERIDE MARKET SIZE, BY MODERATE TO SEVERE BPH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL FINASTERIDE MARKET SIZE, BY MODERATE TO SEVERE BPH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL FINASTERIDE MARKET SIZE, BY MODERATE TO SEVERE BPH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL FINASTERIDE MARKET SIZE, BY MODERATE TO SEVERE BPH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL FINASTERIDE MARKET SIZE, BY MODERATE TO SEVERE BPH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL FINASTERIDE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL FINASTERIDE MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL FINASTERIDE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL FINASTERIDE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL FINASTERIDE MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL FINASTERIDE MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL FINASTERIDE MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL FINASTERIDE MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL FINASTERIDE MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL FINASTERIDE MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL FINASTERIDE MARKET SIZE, BY PRIVATE HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL FINASTERIDE MARKET SIZE, BY PRIVATE HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL FINASTERIDE MARKET SIZE, BY PRIVATE HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL FINASTERIDE MARKET SIZE, BY PRIVATE HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL FINASTERIDE MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL FINASTERIDE MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL FINASTERIDE MARKET SIZE, BY PUBLIC HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL FINASTERIDE MARKET SIZE, BY PUBLIC HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL FINASTERIDE MARKET SIZE, BY PUBLIC HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL FINASTERIDE MARKET SIZE, BY PUBLIC HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL FINASTERIDE MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL FINASTERIDE MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL FINASTERIDE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL FINASTERIDE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL FINASTERIDE MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL FINASTERIDE MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL FINASTERIDE MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL FINASTERIDE MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL FINASTERIDE MARKET SIZE, BY MANUFACTURER WEBSITE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL FINASTERIDE MARKET SIZE, BY MANUFACTURER WEBSITE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL FINASTERIDE MARKET SIZE, BY MANUFACTURER WEBSITE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL FINASTERIDE MARKET SIZE, BY MANUFACTURER WEBSITE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL FINASTERIDE MARKET SIZE, BY MANUFACTURER WEBSITE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL FINASTERIDE MARKET SIZE, BY MANUFACTURER WEBSITE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL FINASTERIDE MARKET SIZE, BY THIRD PARTY E-RETAILER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL FINASTERIDE MARKET SIZE, BY THIRD PARTY E-RETAILER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL FINASTERIDE MARKET SIZE, BY THIRD PARTY E-RETAILER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL FINASTERIDE MARKET SIZE, BY THIRD PARTY E-RETAILER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL FINASTERIDE MARKET SIZE, BY THIRD PARTY E-RETAILER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL FINASTERIDE MARKET SIZE, BY THIRD PARTY E-RETAILER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL FINASTERIDE MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL FINASTERIDE MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL FINASTERIDE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL FINASTERIDE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL FINASTERIDE MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL FINASTERIDE MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL FINASTERIDE MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL FINASTERIDE MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL FINASTERIDE MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL FINASTERIDE MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL FINASTERIDE MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL FINASTERIDE MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL FINASTERIDE MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL FINASTERIDE MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL FINASTERIDE MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL FINASTERIDE MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL FINASTERIDE MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL FINASTERIDE MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL FINASTERIDE MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL FINASTERIDE MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL FINASTERIDE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL FINASTERIDE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL FINASTERIDE MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL FINASTERIDE MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL FINASTERIDE MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL FINASTERIDE MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL FINASTERIDE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL FINASTERIDE MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL FINASTERIDE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL FINASTERIDE MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL FINASTERIDE MARKET SIZE, BY DERMATOLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL FINASTERIDE MARKET SIZE, BY DERMATOLOGY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL FINASTERIDE MARKET SIZE, BY DERMATOLOGY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL FINASTERIDE MARKET SIZE, BY DERMATOLOGY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL FINASTERIDE MARKET SIZE, BY DERMATOLOGY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL FINASTERIDE MARKET SIZE, BY DERMATOLOGY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL FINASTERIDE MARKET SIZE, BY UROLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL FINASTERIDE MARKET SIZE, BY UROLOGY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL FINASTERIDE MARKET SIZE, BY UROLOGY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL FINASTERIDE MARKET SIZE, BY UROLOGY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL FINASTERIDE MARKET SIZE, BY UROLOGY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL FINASTERIDE MARKET SIZE, BY UROLOGY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL FINASTERIDE MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL FINASTERIDE MARKET SIZE, BY HOME CARE, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL FINASTERIDE MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL FINASTERIDE MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL FINASTERIDE MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL FINASTERIDE MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL FINASTERIDE MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL FINASTERIDE MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL FINASTERIDE MARKET SIZE, BY SELF MEDICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL FINASTERIDE MARKET SIZE, BY SELF MEDICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL FINASTERIDE MARKET SIZE, BY SELF MEDICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL FINASTERIDE MARKET SIZE, BY SELF MEDICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL FINASTERIDE MARKET SIZE, BY SELF MEDICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL FINASTERIDE MARKET SIZE, BY SELF MEDICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL FINASTERIDE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL FINASTERIDE MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL FINASTERIDE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL FINASTERIDE MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL FINASTERIDE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL FINASTERIDE MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL FINASTERIDE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL FINASTERIDE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL FINASTERIDE MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL FINASTERIDE MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL FINASTERIDE MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL FINASTERIDE MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL FINASTERIDE MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL FINASTERIDE MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL FINASTERIDE MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL FINASTERIDE MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL FINASTERIDE MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL FINASTERIDE MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL FINASTERIDE MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL FINASTERIDE MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL FINASTERIDE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL FINASTERIDE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS FINASTERIDE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS FINASTERIDE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS FINASTERIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS FINASTERIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS FINASTERIDE MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS FINASTERIDE MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS FINASTERIDE MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS FINASTERIDE MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS FINASTERIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS FINASTERIDE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS FINASTERIDE MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS FINASTERIDE MARKET SIZE, BY BRANDED, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS FINASTERIDE MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS FINASTERIDE MARKET SIZE, BY GENERIC, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS FINASTERIDE MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS FINASTERIDE MARKET SIZE, BY STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS FINASTERIDE MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS FINASTERIDE MARKET SIZE, BY ANDROGENIC ALOPECIA, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS FINASTERIDE MARKET SIZE, BY ANDROGENIC ALOPECIA, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS FINASTERIDE MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS FINASTERIDE MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS FINASTERIDE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS FINASTERIDE MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 291. AMERICAS FINASTERIDE MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 292. AMERICAS FINASTERIDE MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 293. AMERICAS FINASTERIDE MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 294. AMERICAS FINASTERIDE MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 295. AMERICAS FINASTERIDE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 296. AMERICAS FINASTERIDE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 297. AMERICAS FINASTERIDE MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 298. AMERICAS FINASTERIDE MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 299. AMERICAS FINASTERIDE MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
  • TABLE 300. AMERICAS FINASTERIDE MARKET SIZE, BY HOME CARE, 2025-2032 (USD MILLION)
  • TABLE 301. AMERICAS FINASTERIDE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 302. AMERICAS FINASTERIDE MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA FINASTERIDE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 304. NORTH AMERICA FINASTERIDE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 305. NORTH AMERICA FINASTERIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 306. NORTH AMERICA FINASTERIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 307. NORTH AMERICA FINASTERIDE MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 308. NORTH AMERICA FINASTERIDE MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 309. NORTH AMERICA FINASTERIDE MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 310. NORTH AMERICA FINASTERIDE MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 311. NORTH AMERICA FINASTERIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 312. NORTH AMERICA FINASTERIDE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 313. NORTH AMERICA FINASTERIDE MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
  • TABLE 314. NORTH AMERICA FINASTERIDE MARKET SIZE, BY BRANDED, 2025-2032 (USD MILLION)
  • TABLE 315. NORTH AMERICA FINASTERIDE MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
  • TABLE 316. NORTH AMERICA FINASTERIDE MARKET SIZE, BY GENERIC, 2025-2032 (USD MILLION)
  • TABLE 317. NORTH AMERICA FINASTERIDE MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 318. NORTH AMERICA FINASTERIDE MARKET SIZE, BY STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 319. NORTH AMERICA FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 320. NORTH AMERICA FINASTERIDE MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 321. NORTH AMERICA FINASTERIDE MARKET SIZE, BY ANDROGENIC ALOPECIA, 2018-2024 (USD MILLION)
  • TABLE 322. NORTH AMERICA FINASTERIDE MARKET SIZE, BY ANDROGENIC ALOPECIA, 2025-2032 (USD MILLION)
  • TABLE 323. NORTH AMERICA FINASTERIDE MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, 2018-2024 (USD MILLION)
  • TABLE 324. NORTH AMERICA FINASTERIDE MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, 2025-2032 (USD MILLION)
  • TABLE 325. NORTH AMERICA FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 326. NORTH AMERICA FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 327. NORTH AMERICA FINASTERIDE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 328. NORTH AMERICA FINASTERIDE MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 329. NORTH AMERICA FINASTERIDE MARKET SIZE, BY ONLINE PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 330. NORTH AMERICA FINASTERIDE MARKET SIZE, BY ONLINE PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 331. NORTH AMERICA FINASTERIDE MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 332. NORTH AMERICA FINASTERIDE MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 333. NORTH AMERICA FINASTERIDE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 334. NORTH AMERICA FINASTERIDE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 335. NORTH AMERICA FINASTERIDE MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 336. NORTH AMERICA FINASTERIDE MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 337. NORTH AMERICA FINASTERIDE MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
  • TABLE 338. NORTH AMERICA FINASTERIDE MARKET SIZE, BY HOME CARE, 2025-2032 (USD MILLION)
  • TABLE 339. NORTH AMERICA FINASTERIDE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 340. NORTH AMERICA FINASTERIDE MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 341. LATIN AMERICA FINASTERIDE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 342. LATIN AMERICA FINASTERIDE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 343. LATIN AMERICA FINASTERIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 344. LATIN AMERICA FINASTERIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 345. LATIN AMERICA FINASTERIDE MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 346. LATIN AMERICA FINASTERIDE MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 347. LATIN AMERICA FINASTERIDE MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 348. LATIN AMERICA FINASTERIDE MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 349. LATIN AMERICA FINASTERIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 350. LATIN AMERICA FINASTERIDE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 351. LATIN AMERICA FINASTERIDE MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
  • TABLE 352. LATIN AMERICA FINASTERIDE MARKET SIZE, BY BRANDED, 2025-2032 (USD MILLION)
  • TABLE 353. LATIN AMERICA FINASTERIDE MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)

TABLE 35